Overview

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

North American Consortium for Histiocytosis

Collaborator:

Histiocyte Society

Treatments:

6-Mercaptopurine
Antibodies
Cladribine
Cytarabine
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Indomethacin
Mercaptopurine
Methotrexate
Prednisone
Rho(D) Immune Globulin
Vinblastine